Skip to content

Comparative Effects of Wurn Technique and Mercier Therapy in Women With Endometriosis

Comparative Effects of Wurn Technique and Mercier Therapy on Dyspareunia, Dysmenorrhea, and Quality of Life in Women With Endometriosis

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06460376
Enrollment
26
Registered
2024-06-14
Start date
2024-06-30
Completion date
2024-09-30
Last updated
2024-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Dyspareunia, Dysmenorrhea, endometriosis

Brief summary

This project was a Randomized controlled trial conducted to check the comparative effects of wurn technique and mercier therapy on dyspareunia, dysmenorrhea, and quality of life in women with endometriosis. The duration was 6 months, convenient sampling was done, subjects following eligibility criteria from DHQ Hospital Narowal and THQ Hospital Shakargarh were randomly assigned, a baseline assessment was done, Group A participants were given baseline treatment along with wurn technique 2 sessions per week for 6 weeks, Group B participants were given baseline treatment along with mercier therapy 1 session per week for 6 weeks, the post-intervention assessment was done, via the Marinoff Scale, Mankoski Pain Scale and Endometriosis Health Profile Questionnaire (EHP 30). Data was analyzed by using SPSS version 26. Detailed Description: Endometriosis

Detailed description

Endometriosis is the condition involving the presence of glands or stroma of the endometrial lining outside the uterus cavity. Its characteristics include unpleasant pain in the pelvic region, impaired fertility, pain during or after sex, and heavy bleeding during periods. Endometriosis occurs as a result of genetic, angiogenic, immunological, and inflammatory factors. In endometriosis, adhesions may be formed due to local inflammation. It can also occur as the blood-filled implants start bleeding in their surroundings. As a result of this bleeding healing occurs which causes scar formation. Pharmacologically, NSAIDS are used for instant pain relief. The most common surgical approach is laparoscopy. Physiotherapy in its various forms can be an excellent complement to the gynecological treatment of endometriosis. as previous studies also reported the effect of pelvic massage, pelvic manipulation, kinesiotherapy, and hydrotherapy. According to researcher knowledge, there is limited evidence on wurn technique and mercier therapy and how these techniques improve dyspareunia, dysmenorrhea, and quality of life in women with endometriosis. This study aims to see the comparative effects of wurn technique and mercier therapy on dyspareunia, dysmenorrhea, and quality of life in women with endometriosis.

Interventions

Treatment: Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left. To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat. Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment.

OTHERMercier Therapy

Treatment: The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Manual poking, pressing, and massage actions do three things: Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely. Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment

Sponsors

Riphah International University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 43 Years
Healthy volunteers
No

Inclusion criteria

* Age ranging from 25-43(17) * Diagnosed patients with endometriosis * BMI (18.5-29.9),(normal and overweight) * Multigravida * Mode of delivery: vaginal delivery or c section both * Females having grade 1 or 2 grade on the dyspareunia scale * Females having moderate scores on EHP -30

Exclusion criteria

* Malignancy * Pregnancy * Fibroids * Pelvic congestion syndrome * Pelvic inflammatory disease * Females having IUD (inter uterine device) * Recent abdominal or pelvic surgery * Ovarian abscess

Design outcomes

Primary

MeasureTime frameDescription
Endometriosis Health Profile Questionnaire (EHP 30)6 WeeksEndometriosis health profile questionnaire (EHP 30) is to evaluate the suitably self- report health status. It involves 30 items to identify the health status of patients with endometriosis.A core questionnaire which consists of five scales (pain, control and powerlessness, emotional well-being support and self-image). Internal consistency reliability is high for all dimensions (alpha ranged from 0.84 to 0.91)

Secondary

MeasureTime frameDescription
Mankoski Pain Scale6 weeksThe Mankoski Pain Scale is a numerical scale ranging from zero to 10: zero indicates no pain and 10 represents pain so severe that an individual loses consciousness. It will be used to indicate dysmenorrhea.The reliability of mankoski scale is 0.84

Other

MeasureTime frameDescription
Marinoff Scale6 weeksMarinoff scale is used to evaluate dyspareunia. It includes 4 choices with a score of 0-3. Reliability of the scale was obtained with a Cronbach's alpha of 0.94

Countries

Pakistan

Contacts

Primary ContactImran Amjad, PhD
imran.amjad@riphah.edu.pk03324390125
Backup ContactImran Amjad, PhD
imran.amjad@riphah.edu.pk051-5481826

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026